ARGOLYN BIOSCIENCE, INC.

Basic Information

ARGOLYN BIOSCIENCE, INC.
2750 Speissegger Drive, Suite 110
NORTH CHARLESTON, SC, -

Company Profile

n/a

Additional Details

Field Value
DUNS: n/a
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Development of Neurotensin-based Analgesics

    Amount: $163,945.00

    DESCRIPTION (provided by applicant): Chronic, neuropathic pain is one of the most important unmet medical needs in the United States, affecting tens to hundreds of millions of people nationwide at som ...

    SBIR Phase I 2006 Department of Health and Human Services
  2. Novel Neurotensin Analogs as Antischizophrenics

    Amount: $3,000,000.00

    DESCRIPTION (provided by applicant): This is the follow-on Phase II SBIR proposal to continue the project Novel Neurotensin Analogs as Antischizophrenics (MH-65099) under PA-06-079 (Pharmacological ...

    SBIR Phase II 2005 Department of Health and Human Services
  3. NON-NATURAL AMINO ACIDS IN PEPTIDE DRUG DEVELOPMENT

    Amount: $125,279.00

    Argolyn Bioscience Inc. is an early stage biotechnology company that creates novel peptide drugs and diagnostics with greatly improved intrinsic pharmaceutical properties through substitution of non-n ...

    STTR Phase I 2002 Department of Health and Human Services
  4. NOVEL NEUROTENSIN ANALOGS AS ANTISCHIZOPRENICS

    Amount: $139,466.00

    DESCRIPTION (provided by applicant): The brain peptide neurotensin (NT) and its active derivative NT [8-13] function as endogenous neuroleptics. Stable NT derivatives that cross the blood brain barrie ...

    STTR Phase I 2002 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government